AZD0914

DRUG4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Entasis Therapeutics

Conditions

Electrocardiogram Repolarisation AbnormalityGonococcal InfectionGonorrhoeaHealthy

Phase 1

AZD0914 Phase 1 ADME Study in Healthy Volunteers

CompletedNCT02298920

Entasis TherapeuticsHealthy

Start: 2015-01-31End: 2015-02-28Target: 6Updated: 2015-06-03

A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers

CompletedNCT03404167

National Institute of Allergy and Infectious Diseases (NIAID)Gonorrhoea

Start: 2018-02-02End: 2018-03-02Updated: 2019-03-18

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

CompletedNCT03613649

National Institute of Allergy and Infectious Diseases (NIAID)Electrocardiogram Repolarisation Abnormality, Gonococcal Infection

Start: 2018-09-25End: 2019-01-02Updated: 2020-03-27

Phase 2

Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea

CompletedNCT02257918

National Institute of Allergy and Infectious Diseases (NIAID)Gonorrhoea

Start: 2014-11-25End: 2015-12-30Updated: 2017-03-22

Related Papers

Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults.

2021-10-046 citations

Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers.

2018-12-2118 citations

Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea

New England Journal of Medicine2018-11-07219 citations